Home
Scholarly Works
How to Measure Disease Activity, Impact, and...
Journal article

How to Measure Disease Activity, Impact, and Control in Patients with Recurrent Wheals, Angioedema, or Both

Abstract

Chronic spontaneous urticaria and chronic inducible urticaria are characterized by wheals, angioedema, or both, whereas other conditions such as hereditary angioedema present only with angioedema. The unpredictability of outbreaks, disfigurement, pruritus, and associated sleep and work disturbance can cause a significant impact on quality of life (QoL). Significant breakthroughs in the understanding of these conditions in recent years have led to the development of novel therapies. Assessment of patients with these conditions not only focuses on the clinical activity of the condition, but also on the impact on QoL and disease control with treatment. Patient-reported outcome measures, especially if sufficiently validated, give due prominence to the patient's perspective regarding disease impact and treatment outcomes. This article will review the tools readily available to assess activity, impact, and control in patients with recurrent wheals, angioedema, or both.

Authors

Katelaris CH; Lima H; Marsland A; Weller K; Shah A; Waserman S

Journal

The Journal of Allergy and Clinical Immunology In Practice, Vol. 9, No. 6, pp. 2151–2157

Publisher

Elsevier

Publication Date

June 1, 2021

DOI

10.1016/j.jaip.2021.02.026

ISSN

2213-2198

Contact the Experts team